Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Monsma, David J ^a   Monks, Noel R ^a   Cherba, David M ^a   Dylewski, Dawna ^a   Eugster, Emily ^a   Jahn, Hailey ^a   Srikanth, Sujata ^a   Scott, Stephanie B ^a   Richardson, Patrick J ^a   Everts, Robin E ^b   Ishkin, Aleksandr ^c   Nikolsky, Yuri ^c   Resau, James H ^a   Sigler, Robert ^d   Nickoloff, Brian J ^a   Webb, Craig P ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b SEQUENOM INC   (United States)

^c GeneGo bioinformatics software Inc   (United States)

^d Research Essential Services LLC   (United States)

Author keywords

Genomics; Translational models; Tumorgrafts

Indexed keywords

TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; BREAST CANCER; CANCER GENETICS; CANCER GRAFT; CANCER PATIENT; CANCER TISSUE; CELL CYCLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; ENDOCRINE TUMOR; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENOMIC INSTABILITY; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; MUSCLE CANCER; NEUROBLASTOMA; NONHUMAN; ONCOGENE; SIGNAL TRANSDUCTION; SKIN CANCER; SOMATIC MUTATION; UROGENITAL TRACT CANCER;

ANIMALS; GENOMICS; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASMS;

EID: 84862240414     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-125     Document Type: Article

References (50)

1. Cobb LM. The behaviour of carcinoma of the large bowel in man following transplantation into immune-deprived mice. Br J Cancer 1973, 28:400-411. 10.1038/bjc.1973.165, 2008916, 4357133.
2. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Lohr GW. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 1984, 74:343-352.
3. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009, 101:6-8.
4. Houghton JA, Taylor DM. Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 1978, 37:199-212. 10.1038/bjc.1978.28, 2009589, 629858.
5. Fiebig HH, Widmer K-H, Fiedler L, WIttekind C, Lohr GW. Development and Characterization of 51 Human Tumor Models for Large Bowel, Stomach and Esophageal Cancers. Dig Surg 1984, 1:225-235.
6. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001, 84:1424-1431. 10.1054/bjoc.2001.1796, 2363645, 11355958.
7. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003, 9:4227-4239.
8. Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010, 16:974-975. 10.1038/nm0910-974, 20823880.
9. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007, 2:247-250. 10.1038/nprot.2007.25, 17406581.
10. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad O, Langdon S, Fiebig HH. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 1992, 52:5940-5947.
11. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther 2011, 8:1311-1316.
12. Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005, 11:6950-6958. 10.1158/1078-0432.CCR-05-0740, 16203787.
13. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007, 49:928-940. 10.1002/pbc.21078, 17066459.
14. Meyer WH, Houghton JA, Houghton PJ, Webber BL, Douglass EC, Look AT. Development and characterization of pediatric osteosarcoma xenografts. Cancer Res 1990, 50:2781-2785.
15. Mischek D, Steinborn R, Petznek H, Bichler C, Zatloukal K, Sturzl M, Gunzburg WH, Hohenadl C. Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers. J Biomed Biotechnol 2009, 2009:437284. 2655652, 19300524.
16. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006, 12:4652-4661. 10.1158/1078-0432.CCR-06-0113, 16899615.
17. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572-4583. 10.1158/1078-0432.CCR-07-5090, 18628472.
18. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007, 67:32-40. 10.1158/0008-5472.CAN-06-0610, 17210681.
19. Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, Garcia-Garcia E, Lopez-Rios F, Matsui W, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009, 8:310-314. 10.1158/1535-7163.MCT-08-0924, 3033101, 19174553.
20. Pearce M, Culinan A, Hogg G, Hosseni D, Ehrich M. Mutation profiling in tumor samples using the Sequenom OncoCarta™ Panel. Nature Methods 2009, 6:vii-viii.
21. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007, 39:347-351. 10.1038/ng1975, 17293865.
22. Nikolsky Y, Kirillov E, Zuev R, Rakhmatulin E, Nikolskaya T. Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. Methods Mol Biol 2009, 563:177-196. 10.1007/978-1-60761-175-2_10, 19597786.
23. Zheng Q, Wang XJ. GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis. Nucleic Acids Res 2008, 36:W358-W363. 10.1093/nar/gkn276, 2447756, 18487275.
24. Fiebig HH, Neumann HA, Henss H, Koch H, Kaiser D, Arnold H. Development of three human small cell lung cancer models in nude mice. Recent Results Cancer Res 1985, 97:77-86. 10.1007/978-3-642-82372-5_8, 2986247.
25. Houghton JA, Williams LG, Torrance PM, Houghton PJ. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas. Cancer Res 1984, 44:582-590.
26. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton PJ. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999, 5:3617-3631.
27. Dobrolecki LE, Landis MD, Zhang X, Huang J, Lai Q, Wong H, Contreras A, Vahdat LD, Lewis MT CCJ. Preclinical utility of xenografted human breast cancer tumor models. Keystone Symposia-Stem Cells, Cancer and Metastasis; March 6-11, 2011 2011, Keystone, CO, Silverthorne, CO.
28. Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res 2012, 18:1630-1640. 10.1158/1078-0432.CCR-11-2432, 22383738.
29. Malaise M, Neumeier M, Botteron C, Dohner K, Reinhardt D, Schlegelberger B, Gohring G, Gruhn B, Debatin KM, Corbacioglu S. Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice. Leukemia 2011, 25:1635-1639. 10.1038/leu.2011.121, 21647161.
30. Garber K. Personal mouse colonies give hope for pancreatic cancer patients. J Natl Cancer Inst 2007, 99:105-107. 10.1093/jnci/djk046, 17227991.
31. Vilardell F, Iacobuzio-Donahue CA. Cancer gene profiling in pancreatic cancer. Methods Mol Biol 2010, 576:279-292.
32. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010, 7:251-265. 10.1038/nrclinonc.2010.41, 20351699.
33. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010, 19:157-163. 10.1097/PDM.0b013e3181c93fd1, 2929976, 20736745.
34. Shepherd C, Puzanov I, Sosman JA. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 2010, 12:146-152. 10.1007/s11912-010-0095-2, 20425073.
35. Hu T, Li C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer 2010, 9:236. 2944186, 20828404.
36. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy 2011, 3:213-227. 10.2217/imt.10.99, 21322760.
37. Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 2009, 69:2550-2558. 10.1158/0008-5472.CAN-08-1808, 19244133.
38. Nisolle M, Casanas-Roux F, Marbaix E, Jadoul P, Donnez J. Transplantation of cultured explants of human endometrium into nude mice. Hum Reprod 2000, 15:572-577. 10.1093/humrep/15.3.572, 10686198.
39. Shimoda M, Chen S, Noguchi H, Matsumoto S, Grayburn PA. In vivo non-viral gene delivery of human vascular endothelial growth factor improves revascularisation and restoration of euglycaemia after human islet transplantation into mouse liver. Diabetologia 2010, 53:1669-1679. 10.1007/s00125-010-1745-5, 20405100.
40. Abir R, Fisch B, Jessel S, Felz C, Ben-Haroush A, Orvieto R. Improving posttransplantation survival of human ovarian tissue by treating the host and graft. Fertil Steril 2011, 95:1205-1210. 10.1016/j.fertnstert.2010.07.1082, 20817170.
41. Pelleitier M, Montplaisir S. The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol 1975, 7:149-166.
42. Kanwar JR, Berg RW, Yang Y, Kanwar RK, Ching LM, Sun X, Krissansen GW. Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Ther 2003, 10:468-476. 10.1038/sj.cgt.7700590, 12768192.
43. Stewart CA, Vivier E. Strategies of Natural Killer (NK) Cell Recognition and Their Roles in Tumor Immunosurveillance. How the Immune System Recognizes Self and Nonself Volume 2008, 37-81. Springer, New York, Kitamura D.
44. Ohyama C, Kanto S, Kato K, Nakano O, Arai Y, Kato T, Chen S, Fukuda MN, Fukuda M. Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides. Proc Natl Acad Sci U S A 2002, 99:13789-13794. 10.1073/pnas.212456599, 129776, 12370411.
45. Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci 1995, 36:435-441.
46. Hansson M, Bakacs KK, Kiessling R, Klein G. Intra- and interspecies reactivity of human and mouse natural killer (NK) cells. J Immunol 1978, 121:6-12.
47. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999, 59:1295-1300.
48. Welsh RM. Mouse natural killer cells: induction specificity, and function. J Immunol 1978, 121:1631-1635.
49. Shouval D, Rager-Zisman B, Quan P, Shafritz DA, Bloom BR, Reid LM. Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus. J Clin Invest 1983, 72:707-717. 10.1172/JCI111020, 1129230, 6192149.
50. Carroll JL, Nielsen LL, Pruett SB, Mathis JM. The role of natural killer cells in adenovirus-mediated p53 gene therapy. Mol Cancer Ther 2001, 1:49-60.